Flyer
Quanterix empowers researchers with cutting-edge Simoa® digital immunoassays that measure both established and emerging biomarkers in neurology. Simoa® technology sets the gold standard for early biomarker detection in serum, plasma, or CSF, quantifying proteins at levels far below the conventional ELISA Level of Quantification (LoQ). Rely on our industry-leading precision instruments, Simoa® digital immunoassay technology, and CLIA-certified Accelerator laboratory to support research that advances our understanding and management of neurological disorders. Download our flyer to learn more.
Related Posts
Building Custom High-Plex Biomarker Panels
Scale Your Spatial Discoveries with Molecular Barcoding
Spatial Analysis
PhenoCode Molecular Barcoding Kit
Introducing the Metabolism Spike-in Module for IO60
Neurology
NfL Fact Sheet
Neurofilament light (NfL) has emerged in recent years as a blood-based biomarker with the potential to aid in the improvement of early diagnosis and patient care of neuro-axonal injury and…
Neurology
Cytokine 4-Plex Advantage PLUS Product Flyer
Ultra-Sensitive, Fully Automated Simoa® Cytokine 4-Plex Advantage PLUS Assays Three panels, 11 essential cytokine biomarkers, femtogram sensitivity With Simoa® ultra-sensitive protein quantification, the cutting-edge Advantage PLUS assay platform, and full…
PhenoCode Discovery Immune Activation and Proliferation Human Protein Module
Neurology
Brain-Derived Tau (BD-Tau) Fact Sheet
Brain-derived Tau (BD-Tau) is one of the latest additions to the growing neurology biomarker family that holds promise to improve the accuracy in the identification and staging of neurodegeneration in…